Genetron Health Enters Exclusive Global Licensing Agreement with ImmuQuad Biotechnologies to Develop and Commercialize Minimal Residual Disease Assays in Hematologic Cancer - Seite 3

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and research & development plans under the licensing agreement with ImmuQuad. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact
US:
Hoki Luk
Head of Investor Relations
Email: [e-mail]
Phone: [phone]

Stephanie Carrington
Westwicke, an ICR Company
Email: [e-mail]
Office: [phone]

Asia:
Bill Zima
ICR, Inc.
Email: [e-mail]
[e-mail]

Media Relations Contact
Edmond Lococo
ICR
[e-mail]
Mobile: [phone]
[e-mail]